WebApr 12, 2024 · Results of the phase 3 CheckMate 816 trial (NCT02998528) showed a statistically significant and clinically meaningful improvement in event-free survival (EFS) with neoadjuvant nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone for patients with resectable non–small cell lung cancer (NSCLC), representing a new … WebMar 4, 2024 · This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC. Efficacy was evaluated in CHECKMATE-816 (NCT02998528), a randomized, open label trial in patients with...
AACR 2024 - medscape.com
http://www.ioncol.com/article/NewsInfo.aspx?id=8420 chiseled countertop edge
AACR 2024: Combination immunotherapy treatment effective
WebMay 20, 2024 · In the CheckMate 816 trial, people with early-stage non-small cell lung cancer (stage IB to IIIA) received either nivolumab (Opdivo) and chemotherapy or … WebApr 25, 2024 · In the randomized CheckMate 816 study, the authors enrolled adults with stage IB to IIIA resectable NSCLC, an Eastern Cooperative Oncology Group … WebApr 10, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results from the CheckMate -816 study, which showed that neoadjuvant treatment with three cycles of Opdivo (nivolumab) plus chemotherapy significantly improved pathologic complete response (pCR), a primary endpoint, compared to chemotherapy … chiseled define